The novel coronavirus has been spreading since December 2019. It was initially reported in Wuhan, Hubei province of China. Coronavirus disease 2019 (COVID-19) has currently become a pandemic affecting over six millions people worldwide, and the number is still rising. Wenzhou, as the first hit city out of Hubei Province, achieved a remarkable success both in containing the outbreak and effective control of the disease. A great record was also observed in Wenzhou for the clinical COVID-19 patients, leading to one of the minimum death rate in China. Researchers and clinical specialists proposed and formulated combined approaches such as CT-scan and molecular assays, as well as chemical or natural medicines helping detection of the virus and mitigation of its effects by using both allopathic and traditional medications. Iranian and Chinese specialists and scientists had a communication in clinical, molecular and pharmaceutical aspects of COVID-19. A proper guideline was prepared according to the experiences of Chinese clinicians managing full spectrum of COVID-19 patients, from relatively mild to highly complex cases. The purpose of this guideline is to serve a reference in the hospital for specialists. So that they may better diagnose cases and provide effective therapies and proposed antiviral and anti-inflammatory drugs for patients.